Biotech Stocks

22nd Century Group is also helping New Zealand become less tobacco-dependent New York-based 22nd Century Group, Inc. (XXII) is known for developing plant-based solutions for

A recent regulatory approval should thrust TRACON’s antibody-based tumor-fighting therapy into a broad, lucrative geographic market The battle against cancer is ongoing, and not limited

As the data proves, ReShape’s direct-to-consumer marketing campaign has been a huge success A vast patient population, and an already FDA-approved product – there are

From elder care and telemedicine to neutraceuticals and more, Novo offers a broad range of solutions Imagine being able to diversify your holdings in the

NeuBase is accelerating the genetic revolution with a new class of broad-based but highly targeted medicines  Based in Pittsburgh, Pennsylvania, NeuBase Therapeutics, Inc. (NBSE) is

Bet on a reduced-risk, global innovator in drug delivery platforms with Lexaria There are plenty of biotechnology businesses that focus entirely on novel drugs. But

There’s no denying the results as Clene revolutionizes the treatment of neurodegenerative disease Seven-figure funding has obvious financial benefits for any business. When it comes

Aravive’s cancer-fighting therapy is targeted, transformative, and fast-tracked for success  A number of deadly and difficult-to-treat diseases, including cancer and fibrosis, share a common underlying

With Medicenna’s Supuerkine Program advancing rapidly, visionary therapies are within reach Clinical-stage immunotherapy company Medicenna Therapeutics Corp. is boldly pursuing medical therapies through proprietary tools